AU2012205763B2 - Anti-TLR4 antibodies and methods of use thereof - Google Patents

Anti-TLR4 antibodies and methods of use thereof Download PDF

Info

Publication number
AU2012205763B2
AU2012205763B2 AU2012205763A AU2012205763A AU2012205763B2 AU 2012205763 B2 AU2012205763 B2 AU 2012205763B2 AU 2012205763 A AU2012205763 A AU 2012205763A AU 2012205763 A AU2012205763 A AU 2012205763A AU 2012205763 B2 AU2012205763 B2 AU 2012205763B2
Authority
AU
Australia
Prior art keywords
antibody
active fragment
tlr4
binds
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012205763A
Other languages
English (en)
Other versions
AU2012205763A1 (en
Inventor
Thierry Berney
Domenico Bosco
Katrien L. De Graaf
Laurianne Santa Giovannoni
Marie Kosco-Vilbois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novimmune SA
Original Assignee
Novimmune SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune SA filed Critical Novimmune SA
Publication of AU2012205763A1 publication Critical patent/AU2012205763A1/en
Application granted granted Critical
Publication of AU2012205763B2 publication Critical patent/AU2012205763B2/en
Priority to AU2017201859A priority Critical patent/AU2017201859B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2012205763A 2011-01-10 2012-01-10 Anti-TLR4 antibodies and methods of use thereof Active AU2012205763B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017201859A AU2017201859B2 (en) 2011-01-10 2017-03-17 Anti-TLR4 Antibodies and Methods of Use Thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161431191P 2011-01-10 2011-01-10
US61/431,191 2011-01-10
PCT/US2012/020717 WO2012096917A1 (en) 2011-01-10 2012-01-10 Anti-tlr4 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017201859A Division AU2017201859B2 (en) 2011-01-10 2017-03-17 Anti-TLR4 Antibodies and Methods of Use Thereof

Publications (2)

Publication Number Publication Date
AU2012205763A1 AU2012205763A1 (en) 2013-08-08
AU2012205763B2 true AU2012205763B2 (en) 2016-12-22

Family

ID=46455425

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012205763A Active AU2012205763B2 (en) 2011-01-10 2012-01-10 Anti-TLR4 antibodies and methods of use thereof
AU2017201859A Active AU2017201859B2 (en) 2011-01-10 2017-03-17 Anti-TLR4 Antibodies and Methods of Use Thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017201859A Active AU2017201859B2 (en) 2011-01-10 2017-03-17 Anti-TLR4 Antibodies and Methods of Use Thereof

Country Status (7)

Country Link
US (4) US8734790B2 (enExample)
EP (2) EP3539987A1 (enExample)
JP (3) JP6289098B2 (enExample)
AU (2) AU2012205763B2 (enExample)
CA (1) CA2824060C (enExample)
ES (1) ES2721378T3 (enExample)
WO (1) WO2012096917A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2173381T1 (sl) * 2007-05-14 2014-01-31 Novimmune Sa Fc receptor-vezavni polipeptidi z modificiranimi efektorskimi funkcijami
JP6289098B2 (ja) * 2011-01-10 2018-03-07 ノビミューン エスアー 抗ｔｌｒ４抗体およびその使用法
HUE037613T2 (hu) * 2012-03-29 2018-09-28 Novimmune Sa Anti-TLR4 antitestek és azok felhasználása
EP3060250A1 (en) 2013-10-22 2016-08-31 NovImmune SA Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers
WO2015082716A1 (en) * 2013-12-06 2015-06-11 Novimmune S.A. Anti-tlr4 antibodies and methods of use thereof
WO2017021552A1 (en) * 2015-08-06 2017-02-09 Novimmune Sa Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
CN109481666B (zh) * 2018-12-21 2020-11-03 江苏省中医院 一种人体血液肿瘤pdx模型的建立方法
WO2021212222A1 (en) * 2020-04-20 2021-10-28 Edesa Biotech Research Inc. Compositions and methods for treatment of acute respiratory distress syndrome
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
MXPA05002514A (es) * 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
ATE544783T1 (de) 2003-12-10 2012-02-15 Novimmune Sa Neutralisierende anti tlr4/md-2 antikörper und verfahren zu deren verwendung
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
US7674884B2 (en) 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
ES2689328T3 (es) * 2004-01-07 2018-11-13 Novartis Vaccines And Diagnostics, Inc. Anticuerpo monoclonal M-CSF-específico y usos del mismo
WO2007041218A2 (en) * 2005-09-30 2007-04-12 Oklahoma Medical Research Foundation Regulation of tool-like receptors on stem cells
SI2173381T1 (sl) 2007-05-14 2014-01-31 Novimmune Sa Fc receptor-vezavni polipeptidi z modificiranimi efektorskimi funkcijami
CN101589491B (zh) 2007-07-24 2011-07-27 松下电器产业株式会社 镍氢电池用负极材料及其处理方法以及镍氢电池
WO2009138494A2 (en) 2008-05-15 2009-11-19 Ablynx N.V. Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors
CN102239180B (zh) * 2008-08-18 2014-12-31 辉瑞大药厂 抗ccr2抗体
JP6289098B2 (ja) * 2011-01-10 2018-03-07 ノビミューン エスアー 抗ｔｌｒ４抗体およびその使用法

Also Published As

Publication number Publication date
AU2017201859B2 (en) 2019-01-03
EP2663330A1 (en) 2013-11-20
AU2017201859A1 (en) 2017-04-06
US9512221B2 (en) 2016-12-06
EP2663330B1 (en) 2019-03-06
EP2663330A4 (en) 2015-07-22
JP2014505056A (ja) 2014-02-27
CA2824060A1 (en) 2012-07-19
EP3539987A1 (en) 2019-09-18
US20120177648A1 (en) 2012-07-12
JP2019081796A (ja) 2019-05-30
US20150010559A1 (en) 2015-01-08
US20170267754A1 (en) 2017-09-21
JP6289098B2 (ja) 2018-03-07
US20200239566A1 (en) 2020-07-30
US10421809B2 (en) 2019-09-24
ES2721378T3 (es) 2019-07-31
JP2017137319A (ja) 2017-08-10
WO2012096917A1 (en) 2012-07-19
CA2824060C (en) 2021-05-11
US8734790B2 (en) 2014-05-27

Similar Documents

Publication Publication Date Title
AU2017201859B2 (en) Anti-TLR4 Antibodies and Methods of Use Thereof
AU2012205763A1 (en) Anti-TLR4 antibodies and methods of use thereof
AU2019246821B2 (en) Anti-cd40 antibodies and uses thereof
RU2769352C2 (ru) Антитела и полипептиды, направленные против cd127
EP1830881B1 (en) Combining therapies targeting multiple toll-like receptors and use thereof
JP5782132B2 (ja) 抗ＣＤ４０抗体のサイレントＦｃ変異体
AU2016315873A1 (en) Humanized anti-CD40 antibodies and uses thereof
US20160176985A1 (en) Humanized monoclonal antibodies and methods of use
WO2019098763A2 (ko) 알파-시누클레인에 대한 항체 및 그 용도
JP2020019824A (ja) 抗ｔｌｒ４抗体およびその使用方法
TW202311293A (zh) 免疫療法之組合及其用途
KR20210021317A (ko) 백혈병 재발의 예방 및 치료를 위한 cd24의 사용 방법
CA2971364C (en) Dicam-specific antibodies and uses thereof
RU2816592C2 (ru) Антитела, индуцирующие иммунную толерантность, индуцированные лимфоциты и терапевтический агент/способ клеточной терапии с использованием индуцированных лимфоцитов
EA049172B1 (ru) АНТИТЕЛА К ИНТЕГРИНУ αvβ8 ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ПОЧЕК

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)